Bastian Ramms, Ph.D.

Postdoctoral Fellow

I am a passionate scientist who obtained his M.S. in biochemistry from Bielefeld University, Germany. During my master’s program, I performed an internship at UCSD, where I worked on lysosomal storage disorders. I then conducted my Ph.D. at UCSD under the supervision of Philip Gordts and Jeff Esko in collaboration with Bielefeld University. During my Ph.D., I studied the impact of antisense-oligonucleotide-mediated targeting of apolipoprotein C-III and angiopoietin-like protein 3, two key modulators of lipid metabolism, on triglyceride-rich lipoprotein metabolism, atherosclerosis, and diabetes. I joined the Sander lab in summer 2019 with the goal to study beta-cell physiology and to explore novel therapeutic strategies for diabetes.



Kegulian NC*, Ramms B*, Horton S, Wang J, Trenchevska O, Nedelkov D, Graham MJ, Lee RG, Yassine HN, Gordts PLSM. (2019) ApoC-III Glycoforms Are Differentially Cleared by Hepatic Triglyceride-Rich Lipoprotein Receptors. Arterioscler Thromb Vasc Biol. In press.  *equal contributors

Ramms B, Patel S, Nora C, Pessentheiner AR, Chang MW, Green CR, Golden GJ, Secrest P, Krauss RM, Metallo CM, Benner C, Alexander VJ, Witztum JL, Tsimikas S, Esko JD, Gordts PLSM. (2019) ApoC-III ASO promotes adipose tissue specific LPL activity in absence of apoE-mediated TRL clearance. J Lipid Res 60:1379-1395.

Tirronen A, Vuorio T, Kettunen S, Hokkanen K, Ramms B, Niskanen H, Laakso H, Kaikkonen MU, Jauhiainen M, Gordts PLSM, Ylä-Herttuala S. (2018) Deletion of lymphangiogenic and angiogenic growth factor VEGF-D leads to severe hyperlipidemia and delayed clearance of chylomicron remnants. Arterioscler Thromb Vasc Biol 38:2327-2337

Ramms B, Gordts PLSM. (2018) Apolipoprotein C-III in triglyceride-rich lipoprotein metabolism. Curr Opin Lipidol 29:171-179.

Pessentheiner AR, Ramms B, Gordts PLSM. (2018) Angptl3 targeting: The power of versatile lipid-lowering. Atherosclerosis 268:185-187.

Ramms B, Gordts PL. (2016) Dietary nitrate struggles in atherosclerosis. Atherosclerosis 245:71-73.

Gordts PL, Nock R, Son NH, Ramms B, Lew I, Gonzales JC, Thacker BE, Basu D, Lee RG, Mullick AE, Graham MJ, Goldberg IJ, Crooke RM, Witztum JL, Esko JD. (2016) ApoC-III inhibits clearance of triglyceride-rich lipoproteins through LDL family receptors. J Clin Invest.126:2855-2866.